Hernandez, Luis
O’Donnell, Malinda
Postma, Maarten
,
Funding for this research was provided by:
University of Groningen
Article History
Accepted: 16 September 2020
First Online: 29 September 2020
Declarations
:
: No funding was received for the conduct of this study or the preparation of this article.
: Luis Hernandez is an employee of Takeda Pharmaceuticals International Co., his role at Takeda Pharmaceuticals is unrelated to this research. Malinda O’Donnell is an employee of Evidera, a company that provides consulting and other research services to pharmaceutical, device, government, and non-government organizations. Her role at Evidera is unrelated to this research. In addition, Malinda O’Donnell reports ownership of stocks in PPD, Inc. Maarten Postma is a Professor at the University of Groningen and has received grants and honoraria from various pharmaceutical companies all unrelated to this research, but sometimes in the area of multiple sclerosis and from companies developing, producing, and marketing multiple sclerosis drugs. He also reports ownership of stocks in Ingress Health and Pharmacoeconomics Advice Groningen.
: Not applicable.
: Not applicable.
: The SAS code used for the data preparation of the MSOAC Placebo Database and used to conduct the statistical analyses is available in the ESM, except for the program to convert RAND-36 to SF-6D utility values, which was licensed for this study by The University of Sheffield. The programs to convert RAND-36 to SF-6D can be requested in The University of Sheffield Licensing website [CitationRef removed]. The MSOAC Placebo Database is available to researchers who submit, and are approved for, a request for access [CitationRef removed]. Calculations using the mixed models are provided in the ESM.
: Not applicable.